YB1-ADC-PDL1

N/A

Report date: 2023/10/25 11:48:08

Base Information

Drug NameYB1-ADC-PDL1
Drug Alias NameYB1-ADC-PDL1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-Programmed death-ligand 1
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesThe University Of Hong Kong
China Registration ClassN/A

Develop Information

Active CompaniesHknd YB1 Pharmaceutical Ltd
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A